Gilead Sciences, Inc. which can be found using ticker (GILD) have now 26 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $125.00 and $73.00 suggesting an average analyst share price target price of $98.88. (at the time of writing). Now with the previous closing price of $91.23 this indicates there is a potential upside of 8.4%. The 50 day MA is $91.65 and the 200 moving average now moves to $77.90. The market capitalization for the company is 112.95B. The current share price for the company is: $90.63 USD
The potential market cap would be $122,422,613,449 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 1007, revenue per share of $22.70 and a 11.96% return on assets.
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.
